AZNAstraZenecaRunning, no new patients
A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)
Non Small Cell Lung Cancer (Stage III)
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 216 (final count)
- Started
- Jul 19, 2018
- Main results expected
- Jan 5, 2024
- Fully finished
- Oct 29, 2027
- Results posted
- Apr 3, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free Survival (PFS) by Blinded Independent Central Review (BICR)
Measured over: Every 8 weeks for first 48 weeks, then every 12 weeks until BICR-confirmed radiological disease progression. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT03521154 · record last updated 2026-08-04 · checked 2026-11-09 15:47 UTC